Follistatin-like 1 and its paralogs in heart development and
cardiovascular disease

J 2022

Follistatin-like 1 and its paralogs in heart development and cardiovascular disease

HOŘÁK, Martin, DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN, David BEDNÁŘ, Julie DOBROVOLNÁ et. al.

Basic information

Original name

Follistatin-like 1 and its paralogs in heart development and cardiovascular disease

Authors

HOŘÁK, Martin (203 Czech Republic, belonging to the institution), DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN (246 Finland, belonging to the institution), David BEDNÁŘ (203 Czech Republic, belonging to the institution) and Julie DOBROVOLNÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

Heart Failure Reviews, New York, Springer US, 2022, 1382-4147

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.600

RIV identification code

RIV/00216224:14310/22:00127632

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1007/s10741-022-10262-6

UT WoS

000828956200001

Keywords in English

FSTL1; FSTL4; FSTL5; Heart failure; Inflammation

Abstract

V originále

Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736-1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.

Links

EF15_003/0000469, research and development project

Name: Cetocoen Plus

EF17_043/0009632, research and development project

Name: CETOCOEN Excellence

LM2018121, research and development project

Name: Výzkumná infrastruktura RECETOX (Acronym: RECETOX RI)

Investor: Ministry of Education, Youth and Sports of the CR, RECETOX RI

NU22-02-00418, research and development project

Name: Klinické a proteomické biomarkery predikující reverzní remodelaci levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií

Investor: Ministry of Health of the CR, Subprogram 1 - standard

857560, interní kód MU
(CEP code: EF17_043/0009632)

Name: CETOCOEN Excellence (Acronym: CETOCOEN Excellence)

Investor: European Union, Spreading excellence and widening participation

Citovat

HOŘÁK, Martin, DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN, David BEDNÁŘ and Julie DOBROVOLNÁ. Follistatin-like 1 and its paralogs in heart development and cardiovascular disease. Heart Failure Reviews. New York: Springer US, 2022, vol. 27, No 6, p. 2251-2265. ISSN 1382-4147. Available from: https://dx.doi.org/10.1007/s10741-022-10262-6.

@article{2243097,
   author = {Hořák, Martin and Fairweather, DeLisa and Kokkonen, Piia Pauliina and Bednář, David and Dobrovolná, Julie},
   article_location = {New York},
   article_number = {6},
   doi = {http://dx.doi.org/10.1007/s10741-022-10262-6},
   keywords = {FSTL1; FSTL4; FSTL5; Heart failure; Inflammation},
   language = {eng},
   issn = {1382-4147},
   journal = {Heart Failure Reviews},
   note = {Korespondenční autor nereagoval na žádost o doplnění podílu. Podíl doplněn rovnocenně podle počtu participujících HS (dle rozhodnutí vedení PřF).},
   title = {Follistatin-like 1 and its paralogs in heart development and cardiovascular disease},
   url = {https://link.springer.com/article/10.1007/s10741-022-10262-6},
   volume = {27},
   year = {2022}
}

TY  - JOUR
ID  - 2243097
AU  - Hořák, Martin - Fairweather, DeLisa - Kokkonen, Piia Pauliina - Bednář, David - Dobrovolná, Julie
PY  - 2022
TI  - Follistatin-like 1 and its paralogs in heart development and cardiovascular disease
JF  - Heart Failure Reviews
VL  - 27
IS  - 6
SP  - 2251-2265
EP  - 2251-2265
PB  - Springer US
SN  - 13824147
N1  - Korespondenční autor nereagoval na žádost o doplnění podílu. Podíl doplněn rovnocenně podle počtu participujících HS (dle rozhodnutí vedení PřF).
KW  - FSTL1
KW  - FSTL4
KW  - FSTL5
KW  - Heart failure
KW  - Inflammation
UR  - https://link.springer.com/article/10.1007/s10741-022-10262-6
N2  - Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels and a leading cause of death worldwide. Thus, there is a need to identify new cardiokines that may protect the heart from damage as reported in GBD 2017 Causes of Death Collaborators (2018) (The Lancet 392:1736-1788). Follistatin-like 1 (FSTL1) is a cardiokine that is highly expressed in the heart and released to the serum after cardiac injury where it is associated with CVD and predicts poor outcome. The action of FSTL1 likely depends not only on the tissue source but also post-translation modifications that are target tissue- and cell-specific. Animal studies examining the effect of FSTL1 in various models of heart disease have exploded over the past 15 years and primarily report a protective effect spanning from inhibiting inflammation via transforming growth factor, preventing remodeling and fibrosis to promoting angiogenesis and hypertrophy. A better understanding of FSTL1 and its homologs is needed to determine whether this protein could be a useful novel biomarker to predict poor outcome and death and whether it has therapeutic potential. The aim of this review is to provide a comprehensive description of the literature for this family of proteins in order to better understand their role in normal physiology and CVD.
ER  -

HOŘÁK, Martin, DeLisa FAIRWEATHER, Piia Pauliina KOKKONEN, David BEDNÁŘ and Julie DOBROVOLNÁ. Follistatin-like 1 and its paralogs in heart development and cardiovascular disease. \textit{Heart Failure Reviews}. New York: Springer US, 2022, vol.~27, No~6, p.~2251-2265. ISSN~1382-4147. Available from: https://dx.doi.org/10.1007/s10741-022-10262-6.

Detailed Information on Publication Record